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Introduction
Methadone maintenance therapy (MMT) is the most effective evidence based treatment for opiate dependence. Most studies
have shown reductions in illicit drug use and improvement on other psychosocial parameters such as legal issues, crime
and risk behaviour1,3. However, the problem of continuing drug use among MMT patients is long standing and widely
acknowledged. Even in studies demonstrating the effectiveness of various interventions for improving treatment response
among MMT patients, a subgroup of patients typically fails to respond. Ball & Ross2 found rates of ongoing injection
drug use as high as 57%. In Australia, Mattick et al4 found that patients maintained on about 55mg methadone tested
positive for opiates in just over 50% of urine samples. In USA, Strain et al5 in 1999 found that patients on high dose
methadone (over 80 mgs) tested positive for opiates in 53% of urine samples while patients on a moderate dose
demonstrated 61.9% positive samples. Using similarly high methadone doses and enhanced psychosocial treatment supports,
Avants et al6 achieved greater opiate abstinence but more than one third of samples were positive for illicit opiates
with the most intensive treatment program. In a review of nine Veterans Administration clinics in USA treating an older
client group, Willenbring et al7 in 2004, found that just 17% of samples provided by clinic attendees were opiate
positive.
Although attempts to identify poor responders have failed to yield consistent predictors, several studies suggest
various factors that might be associated with favourable outcomes. In most previous studies a higher dose of Methadone
is associated with less illicit opiate abuse and longer retention rates in treatment 5,8. There is a significant amount
of evidence that suggests poly−substance abuse seriously compromises treatment. Cocaine/crack abuse is a risk factor for
continued heroin use9,10,11. Contradictory results were obtained during investigation of the effectiveness of psychosocial
programmes associated with Methadone treatment that varies widely among clinics. However, early and more frequent
counselling contacts were associated with lower rates of drug use by patients on MMT 12. While it is generally
recognised that patients who have a comorbid mental disorder in addition to an addiction have poorer treatment outcomes,
there is limited research on the impact of mental disorders on the treatment of opiate dependence 14,13,15.
Identification of the factors that are predictive of outcomes, these might prove useful in modifying intervention
strategies for improved responses. For this reason, we decided to investigate the factors supporting MMT effectiveness
among patients attending drug treatment services at Drug Treatment Centre Board (DTCB) at Trinity Court in Dublin. DTCB
is a central drug treatment service for the whole population of Dublin, which is approximately one million. This service
also provides specialist advice and professional support to community based Methadone clinics and General Practices. The
national advisory committee on drugs (NACD) estimates that there are over 12,500 opiate addicts in Dublin 24.
This is a retrospective study that aimed to measure rates of ongoing heroin abuse among patients on MMT in the Irish
treatment context. We also sought to identify which patient and treatment characteristics are associated with an
improved response to MMT.
Method
Setting
The DTCB is the longest established addiction treatment service in Ireland. The vast majority of clients have a primary
diagnosis of opiate dependence. Treatment is provided by a multidisciplinary team led be a consultant psychiatrist.
Addiction treatment services expanded substantially in Dublin during the 1990s. Many new addiction treatment clinics
were opened and many general practitioners began providing treatment in the community setting to patients addicted to
opiates. There are about eight thousand people on methadone maintenance in Dublin. At any one time, about 500 of these
patients are being treated in DTCB. General practitioners in the community manage the most stable group of patients.
More complex cases are managed in the local addiction treatment services. The most complex patients are managed in the
DTCB. Patients are referred into and out of DTCB to and from other addiction services as their needs change. Patients
attending the DTCB have higher rates of psychiatric comorbidity, serious physical illness, co−dependence on other
substances, homelessness and violent behaviour than their counterparts in other services. The multidisciplinary team
comprises of psychiatrists, nurses, counsellors, social work and outreach. Attendance at counselling is voluntary and
many clients fail to attend following referral. The counselling approaches used draw upon Rogerian psychotherapy and
cognitive therapy.
Data Collection
We included patients who were on MMT throughout a three−month period preceding data collection in 2004. Patients who
dropped out of treatment were not included. Patients who were transferred back to community based addiction treatment
during the three month period were also excluded. These patients were excluded because no, or very few, urine samples
were available for these patients and the key outcome measure in this study was the proportion of the illicit opiate
positive samples provided over a three month period. Patient characteristics including age, gender, duration in
treatment and Methadone dose were obtained from the clinical notes. In order to examine rates of comorbidity, doctors
managing patients identified those patient who had an affective disorder (Depression or Bipolar affective disorder) or a
psychotic disorder (Schizophrenia, schizoaffective disorder or drug induced psychosis), according to ICD 10 criteria at
the outset of the study.
Urine samples were collected from patients one or two times per week. In order to examine characteristics associated
with better outcome, we created a dichotomous variable based on results of urinalysis screens for illicit opiate use. To
maximise our statistical power to identify significant predictors of good outcome we sought to obtain groups of similar
size. An earlier audit of outcome revealed that about half the clients on MMT were opiate positive in less than 20% of
provided urine samples. Therefore we categorised patients as having a good outcome if less than 20% of their urine
samples tested positive for opiates during the study period. Patients with more than 20% samples testing positive for
opiates were categorised as having a poor outcome. There is no international consensus on the proportion of opiate
positive urine samples that constitute a good outcome. As mentioned above, the mean proportion of the opiate positive
samples found among the patients on MMT in the international studies ranges from 17% to 53%, with most studies at the
upper end of this range. Consequently, we suggest that setting the cut−off at 20% has some face validity based on this
international literature.
Urinalysis
Clients provided supervised urine samples between one and two times per week. Each sample is screened for opiates,
cocaine metabolite (benzoylecgonine) and benzodiazepines using Syva® EMITÂ® II Plus homogenous enzyme immunoassay at the
cut−offs of 300ng/ml, 300ng/ml and 200ng/ml respectively. Samples were also tested for amphetamines and ring
substituted amphetamines (e.g. MDMA) using the microgenics CEDIA assay calibrated at a 1000ng/ml alpha amphetamine
cut−off. The test for alcohol is a MicrogenicsÂ® DRIÂ® Ethyl Alcohol Enzymatic Assay at a cut off of 30mg%.
Statistical Analysis
Quantative variables were converted into categorical variables for the purpose of analysis. Associations between
categorical variables and good outcome were examined using Pearsonâ€™s chi square test. Specifically we examined for the
associations of good outcome with gender, age, duration in treatment, Methadone dose, attendance at counselling,
psychiatric co−morbidity and illicit use of other drugs. Odds ratio and their 95% confidence intervals were reported to
indicate the magnitude of associations. A logistic regression analysis was conducted to identify those variables
independently predictive of a good outcome. Variables were chosen for inclusion in the final regression equation by
using the forward and backward selection techniques, based on Wald statistic. All variables examined on univariate
analysis listed above were considered for selection into the final regression equation. The selected variables were
examined for evidence of interaction.
Results
Four hundred and ninety five patients were attending DTCB at the start of this study and 440 patients (89%) who remained
in the treatment for full three month period were included in the study. Sixty−three per cent were male and their mean
age was 32 years. Mean duration in treatment was 42 months. A comorbid psychotic illness was present in 26 (6%) patients
and comorbid affective disorder was present in 121 (27%) patients. The average methadone dose prescribed to patients was
74mgs per day. The methadone dose was over 60mgs in 361 (82%) cases. One hundred and sixty−nine (38%) patients attended
counselling during the study period. However, 47% of these attended counselling less than once per month. Urinalysis
confirmed that 172 (39%) patients abused cocaine during the study period. Two hundred and eighty−one (65%) showed
evidence of benzodiazepine (BZD) abuse (i.e. urinalysis demonstrated benzodiazepine use in the absence of benzodiazepine
prescription). Seventy−five (17%) demonstrated evidence suggestive of alcohol misuse, with urine samples testing
positive for the same. Twenty−two (5%) patients provided urine samples that were regularly positive for alcohol (i.e.
more than one in five samples tested positive). Only 22 (5%) of the patients tested positive for amphetamines during the
study period. Of these, fifteen patients demonstrated amphetamine use in just one urine sample over three month period
of study.
Table 1. Characteristics associated with greater opiate abstinence among 440 patients on methadone maintenance
treatment





Female 58 1.3 (0.9−1.9) 0.21
Age
<30 yrs 51 1.0
=>30 yrs 58 1.3 (0.9−1.9) 0.15
Duration in treatment
Under 24 month 48 1.0
24−59 months 57 1.4 (0.9−2.3) 0.10
=> 60 months 59 1.6 (1.0−2.6) 0.06
Methadone dose
Under 60mg 43 1
At least 60mg 57 1.8 (1.1−2.9) 0.02
Counselling (%)
None 56 1.0
Some 51 0.8 (0.5−1.2) 0.3
Dual Diagnosis
Not psychotic 55 1
Psychosis 54 1.0 (0.4−2.3) 0.97
No affective disorder 53 1




Infrequent use* 45 0.5 (0.3−0.7) 0.001
Regular use* 34 0.3 (0.2−0.5) <0.001
Benzodiazepine
abstinent 65 1.0
Intermittent use^ 44 0.4 (0.2−0.7) 0.002
Consistent use^ 59 0.8 (0.4−1.4) 0.35
Alcohol
No samples positive 55 1.0
Infrequent use* 47 0.7 (0.4−1.3) 0.3
Regular use* 68 1.8 (0.7−4.5) 0.22
* â€œInfrequent useâ€ implies less than 20% of samples revealed presence of the substance and â€œRegular useâ€
implies that more than 20% of samples revealed presence of the substance
^ â€œintermittent useâ€ implies that some, but not all urine tests revealed
Of the 5686 urine samples collected from patients during the study period, 1616 (28%) were opiate positive. One hundred
and forty−seven (34%) patients were abstinent from illicit opiates throughout the study period. A further 90 (20%)
patients demonstrated infrequent illicit opiate misuse, testing positive for opiates in less than 20% of urine samples.
Poorer outcome was significantly associated with lower methadone dose, cocaine abuse and intermittent benzodiazepine use
on both univariate and multivariate analysis (see tables 1 and 2). Patients who were in treatment for a longer period
(greater than 24 months) of time demonstrated lower levels of ongoing illicit opiate abuse (Mantel−Haenszel chi square
test for trend, p=0.05). Outcome was not significantly associated with gender, age, counselling attendance or dual
diagnosis.
Table 2. Factors associated with better outcome among 440 patients on methadone maintenance treatment, on multivariate
analysis
Characteristic Adjusted odds ratio
(AOR)









Infrequent use* 0.4 0.3 − .07 0.001





0.5 0.3 â€“ 0.8 0.009
Consistent use 0.7 0.4 â€“ 1.3 0.30
* â€œInfrequent useâ€ implies less than 20% of samples are cocaine positive and â€œRegular useâ€ implies that more
than 20% of samples were cocaine positive
Thirty−three (43%) of the 77 patients who were receiving less than 60mg of methadone achieved a good outcome, with 22
demonstrating complete abstinence throughout the study period. Fifty patients were being prescribed more than 100 mgs of
methadone. Fourteen (28%) of these failed to achieve a good outcome.
Discussion
Results of our study indicate that many patients were involved in ongoing illicit opiate misuse while on MMT. However,
during the three months of study period one third of patients were opiate abstinent throughout. One in five patients
demonstrated occasional opiate misuse while on MMT, with less than 20% of their urine samples testing opiate positive.
Overall, 72% of urine samples provided by patients were opiate negative. Although findings from urinalysis vary in
different studies 4,5,7,17 these results from DTCB indicate a reasonable outcome for MMT patients in Dublin. Great caution
is needed in evaluating methadone effectiveness reported in various studies as outcomes may be influenced by clinic
policies, programme modalities and client characteristics. The DTCB clients, included in this study, are selected on
the basis of being treatment resistant and difficult to manage in other clinics. Outcomes for patients on MMT in other
treatment settings in Dublin are likely to be different, given the fact that the DTCB is effectively a tertiary referral
service for other settings
Our findings that higher dose of methadone is associated with better outcome in terms of opiate abstinence strengthens
previous evidence5,18. This has been generally acknowledged in most treatment settings. Patients treated with inadequate
doses of methadone commonly supplement their dose with illicit opiates. Treatment response can be maximised by titrating
the dose of methadone in response to clinical signs and subjective distress. There is evidence from previous studies
that most patients do not request inappropriate increases in methadone dosage8. On the other hand, higher doses alone
may not solve the problem of illicit opiate use among methadone non−responders 21. In this study, despite high doses of
Methadone (greater than 100mg) more than one quarter of patients did not achieve good outcome. In a study by Belding 18
57% of non−responders were already on 80mg and 27% were on or above 100mg. In one study by Willenbring7 it was indicated
that the percentage of patients that were successfully being maintained at doses less than 60mg ranged from 17 to 40%,
with average across clinics of 29%. Therefore, simply providing higher doses to everyone will not guarantee a good
outcome for all patients. Close monitoring of all patients who test positive for non medical opiates, regardless of
current dosage, and reviewing the management plan based on individual needs may be a more appropriate approach than
simply titrating up the dose.
This present study confirms previous findings that cocaine and benzodiazepines (BZD) abuse are linked with poorer
outcomes 18,20. This study has shown that patients with positive cocaine samples were much less likely to have a
favourable treatment response than those who avoided cocaine use. There is a need to develop and evaluate both
pharmacological and psychosocial interventions for MMT patients who abuse cocaine 22. This represents a growing
challenge for treatment services as recent research has shown an increasing use of cocaine/crack in the opiate dependent
population in Dublin11,13. This has now become a growing challenge for services. One study 23 has shown that contingency
intervention in conjunction with an intensive CBT protocol is effective in engaging and retaining patients with high
levels of cocaine/crack use. BZD abuse in MMT patients was wide spread in our patient group, a finding that has
previously noted in Dublin . It has been suggested that as a consequence of inadequate methadone dose, some patients
2
take BZD in order to handle heroin craving. If this is true than titration of methadone dose against use of BZD can be
useful in eliminating BZD use in motivated patients. Contrary to our expectations we found increased opiate abuse among
intermittent BZD users while the level of illicit opiate abuse among those constantly BZD positive were similar to
those seen in the group who were BZD abstinent. . One explanation is that the intermittent BZD users are regularly
seeking intoxication or experiencing difficult cravings. On some occasions, they take a handful of tablets and on other
occasions they take heroin. The constant BZD users may be seeking a constant low grade sedation but do not particularly
seek the euphoric effects from heroin anymore. Rates of abuse of amphetamines and ecstasy were low in this group during
study period.
Another unexpected finding of this study was that patients with dual diagnosis tended to do well in terms of opiate
abstinence. We speculate that patients with dual diagnosis were receiving more intensive treatment from the adult mental
heath teams and consequently fared as well as the other patients attending this specialist service. However, the amount
of input from mental health teams was not measured. Enhanced and multidimensional services have been shown to
demonstrate increased effectiveness in substance misuse treatment14,15,25.
Unlike previous studies, this study failed to demonstrate any beneficial effects of counselling 9,12. However, these
results should be interpreted cautiously. It is likely that this finding reflects the manner in which clients access
counselling in DTCB. Out of 440 patients, only 87 attended counselling sessions on a regular basis. Patients with
significant psychosocial problems and treatment resistance are prioritised for the referral to counselling, and many of
them were consistently giving opiate positive samples before referral. Both our clinical experience and previous
evidence suggest that the role of the counsellor is very important in treatment of substance misuse. In the study by
Willenbring7 counselling frequency was positively correlated with better outcome. Counselling practices vary widely
between different clinics. Outcome could be related to counselling skills, strategies and facilities. McLellan 26 has
shown that adequate counselling including weekly sessions for first four weeks of treatment and monthly sessions
thereafter improve outcomes compared to no counselling.
There was a positive correlation between opiate negative results and longer duration in treatment. Although results were
not statistically significant, younger clients tended to demonstrate poorer outcome 27. There are a number of plausible
explanations for poorer outcome among younger patients earlier in the treatment process. These include peer pressure,
more chaotic life styles and lack of education and awareness in this group. There is a growing consensus regarding the
need to develop specialist services tailored to suit the different needs of young drug abusers 28.
There are limitations to this study. The DTCB is a highly specialized drug treatment centre that has a
multidisciplinary staff team and more resources than many other services. In general, patients attending this clinic
have chronic substance misuse problems, complex mental health issues and more serious forensic, social and behavioural
difficulties. In this respect, our cohort differs from those attending other community based substance misuse clinics
and the outcome might be different in such settings. Also, in this study, counselling failed to show an improved
outcome. As mentioned earlier, this could be due to the fact that only a minority of the patients with more serious
psychosocial issues are prioritised for this service. A RCT design would be a more appropriate method to study the
impact of counselling on outcomes. Urinalysis provides a very objective method for identifying ongoing illicit
substance misuse during treatment. However, it is limited by the variability in elimination half−life of drugs. This can
be weeks for benzodiazepines, days for opiates and cocaine and just hours for alcohol. With regard to alcohol abuse,
some might consider it unreasonable to assume that alcohol detected in urine samples is indicative of problematic use.
We did not use structured diagnostic instrument to identify patients with co−morbid psychiatric disorder. We relied on
clinical diagnosis and this is likely to be less reliable in terms of consistency. We confined this study to patients
who were on methadone treatment for the complete three month study period. In doing so, we cannot provide information on
patients who dropped out of treatment, finished treatment or who transferred back to community based treatment during
the study period.
The results achieved by patients in Dublin are quite good by international standards. Services providing MMT should
monitor treatment outcome and develop interventions that strive to assist patients in achieving even higher rates of
abstinence. MMT patients who abuse cocaine and BZD are at an increased risk of continuing opiate abuse and constitute a
growing challenge to treatment services in Dublin.
References
Marsch LA, The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk
behaviour and criminality: a
meta−analysis. Addiction, (1998), 93(4), 515−532.
1. 
Ball JC, Ross A, The effectiveness of methadone maintenance treatment, (New York, Springer−Verlag), (1991).2. 
Gossop M, Marsden J, Stewart D, Lehmann P, Edwards C, Wilson A, Segar G. Substance use, health and social
problems of service users
at fifty four drug treatment agencies: intake data from National treatment outcome research study. British
Journal of Psychiatry, (1998), 173, 166−171.
3. 
Mattick RP, Ali R, White JM, Oâ€™Brien S, Wolk S, DanzC. Buprenorphine versus methadone maintenance therapy:
arandomized double blind trial with 405 opioid−dependent patients. Addiction, (2003), 98, 441−452.
4. 
Strain EC, Bigelow GE, Liebson IA, Stitzer ML, Moderate vs high dose methadone in treatment of opiate
dependence, JAMA, (1999), 281, 11, pg 1000.
5. 
Avants SK, Margolin A, Sindelar JL, Day treatment versus enhanced standard methadone services for
opioid−dependent patients: a comparison of clinical efficacy and cost. American Journal of Psychiatry, (1999),
156, 27−33.
6. 
Willenberg ML, Hagedorn HJ, Postier AC, Kenny M. Variations in evidence based clinical practices in nine United
States veteransâ€™ administration opioid agonist therapy clinics, Drug and Alcohol dependence, (2004), 75,
97−106.
7. 
Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of higher dose methadone,
Journal of psychoactive drugs, (1999), 31, (2), 95−102.
8. 
Alterman AI, Kampman K. A cocaine positive baseline urine predicts outpatient treatment attrition and failure to
attain initial abstinence, Drug and Alcohol dependence, (1997), 46, 79−85.
9. 
Magura S, Rosenblum A, Fong C. Treating cocaine using methadone patients: predictors of outcomes in a
psychosocial clinical trial, Substance use and misuse, (2002), 37, 1927−1955.
10. 
National Advisory Committee on Drugs. An overview of cocaine use in Ireland, (2003), Dublin.11. 
Joe GW, Simpson DD, Relationships between counselling rapport and drug abuse treatment outcomes, American
psychiatric association, (2001), 52, 1223−1229.
12. 
MacGabhann, Scheele A, Dunne T, Gallagher P, MacNeela P, Moore G, Philbin M, Mental health and addiction
services and management of dual diagnosis in Ireland, National Advisory Committee on Drugs, (2004), Dublin.
13. 
Cacciola JS, Alterman AI, The relationship of psychiatric comorbidity to treatment outcomes in methadone
maintained patients, Drug and Alcohol dependence, (2001), 61, 271−280.
14. 
Farrell M, Boys A, Bebbington P, Brugha T, Psychosis and drug dependence: results from a national survey of
prisoners, Britisg Journal of Psychiatry, (2002), 181, 393−398.
15. 
Kelly A et al, Prevalence of opiate use in Ireland, A three source capture recapture study. National Advisory
Committee on Drugs, (2003), Dublin.
16. 
Gerra G, Ferri M, Polidori E, Santoro G, Zaimovic A, Sternieri E, Long term methadone maintenance effectiveness:
psychosocial and pharmacological variables, Journal of substance abuse treatment, (2003), 25, 1−8.
17. 
Belding MA, McLellan T, Zanis DA, Inkmikoski R, Characterizing non−responsive methadone patients, Journal of
substance abuse treatment, (1998), 15 485−492.
18. 
Bleich A, Gelkof M, Weizman T, Adelson M, Benzodiazepine abuse in a methadone maintenance clinic in Israel:
Characteristic and a pharmacotherapeutic approach, The Israel Journal of psychiatry and related sciences,
(2002), 39, 2.
19. 
Bovasso G, Cacciola J, The long term outcomes of drug use by methadone maintenance patients, The Journal of
behavioural health services and research, (2003), 30, 3.
20. 
National treatment agency, More than just methadone dose, drug and alcohol findings, (2004), London.21. 
Roseblum A, Magura S, Enhanced treatment outcomesfor cocaine using methadone patients, Drug and alcohol
dependence, (1999). 54,207−218.
22. 
Villano CL, Rosenblum A, Magura S, Fong C, Improving treatment engagement and outcomes for cocaine using
methadone patients, American Journal of Drug and Alcohol abuse, (2002), 28(2), 213− 230.
23. 
Rooney S, Kelly G, Bamford L, Sloan D, Oâ€™Conner JJ, Co−abuse of opiates and benzodiazepines. Irish journal of
medical sciences, (1999), 168, 36−41.
24. 
Saxon AJ, Calsyn DA, Effects of psychiatric care for dual diagnosis patients treated in a drug dependence
clinic, American journal of drug and alcohol abuse, (1995), 21(3), 303−313.
25. 
McLellan AT, Arndt IO, Metzger DS, Woody GE, Oâ€™Brien CP, The effects of psychosocial services in substance
abuse treatment, Journal of American medical association, (1993), 296(15), 1953− 1959.
26. 
Firoz S, Carlson G, Characteristics and treatment outcome of older methadone maintained patients, The American
Journal of geriatric psychiatry, (2004), 12, 539−541.
27. 
Department of health and children, Report of the working group on treatment of under 18s presenting to treatment
services with serious drug problems. Government Publications, (2005), Dublin.
28. 
3
Comments: Fariha Kamal, <br>Baytrees unit, St. Jamesâ€™ hospital, Locksway road, <br>Portsmouth, PO4 8LD, UK. <br>Email: <a
href=mailto:Fariha.Kamal@ports.nhs.uk>Fariha.Kamal@ports.nhs.uk</a><br>
OtherReferences: No References
Acknowledgement: Richie Maguire and laboratory staff at DTCB.
4
